CYTOMX THERAPEUTICS INC (CTMX)
Health Care · NASDAQ
CytomX is developing conditionally activated cancer therapies using its PROBODY platform to enable selective tumor targeting with reduced systemic toxicity, starting with varsetatug masetecan for colorectal cancer.
What CYTOMX THERAPEUTICS INC does
CytomX Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing conditionally activated biologics using its proprietary PROBODY technology platform. The company leverages tumor-associated proteases to selectively activate therapeutics in the tumor microenvironment, reducing off-target toxicity. Its pipeline includes clinical-stage programs such as varsetatug masetecan (Varseta-M), an antibody-drug conjugate targeting EpCAM for colorectal cancer, and CX-801, both in Phase 1 development.
Themes: ["Oncology / cancer therapeutics"]
Fundamentals
- Price$3.96 as of 2026-07-09 close
- Market cap$828M as of 2026-07-10
- 1-year return+58.8% as of 2026-07-09 close
- Net margin-166.4% as of 2026-07-10
- ROE-36.6% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)-75.9% as of 2026-07-10
- Revenue CAGR (3y)+12.8% SEC XBRL
- Beta2.16 as of 2026-07-10
Key risks (from latest filing)
["Clinical-stage company with no approved products; success dependent on advancing Varseta-M and CX-801 through Phase 1 and later-stage clinical trials with uncertain outcomes"]
Competitors & peers
- Genmab
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.